Global Tumor Necrosis Factor Inhibitors Drug Market By Product Type (Cimzia (Certolizumab Pegol), Enbrel (Etanercept)) And By End-Users/Application (Clinic, Hospital) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 - 2026

  • AMR-985157
  • April 2021
  • Pharmaceuticals
  • 159 Pages

Report Preview

The global Tumor Necrosis Factor Inhibitors Drug market research report provides complete study and detail analysis of the market. This study includes forecast analysis of the market which is based on global and regional level, whereas the research reports the provides forecast data from 2020-2028 and historic of 2018 and 2019. All the values are based on revenue USD Million. Moreover, the market research report describes various segments of the Tumor Necrosis Factor Inhibitors Drug market based on its types, applications and end-use industry. The applications of the market are explained in different industry verticals with reference to major countries across the globe. Along with this, the research report also covers all the major players that are operating in the global Tumor Necrosis Factor Inhibitors Drug market. These major players of the market are further studied and analyzed based on various parameters, such as annual market revenue, annual sales of the company, marketing strategy, historic growth and shipment volumes. Based on all the company’s insights, the market research analyst also suggests business strategy and marketing plans for improving the market position of existing participants of Tumor Necrosis Factor Inhibitors Drug market.

Apart from this, the market research report also covers drivers and restraints for the global Tumor Necrosis Factor Inhibitors Drug market and their impact on the demand and supply during the forecast period. Along with this, the research report also provides Tumor Necrosis Factor Inhibitors Drug market trends and opportunities that are based on regional and global level. Furthermore, the market research report also provides the major distributors and manufacturers that are operating in all the key region across the world. The researched data provided in the report is widely used by various industry players to strengthen their distribution channel and improve the geographical reach. In addition, the report also covers all the major players of the global Tumor Necrosis Factor Inhibitors Drug market and its key offerings and solutions. The report also provides recent mergers and acquisitions of these key players.

XYZ Market Strategic Analysis:
In 2019, the global XYZ market was valued at US$ xx Mn, and it is expected to reach at US$ xx Mn at a CAGR of xx% during 2020-2028.

The data which is provided in the market research report is analyzed and evaluated with the help of various marketing tools, such as SWOT analysis, Poster’s Five Force analysis, PESTEL analysis, value chain analysis, player positioning analysis and market share analysis. Therefore, this analysis tools helps the analyst to evaluate the Tumor Necrosis Factor Inhibitors Drug market based on various parameters such as capital investments, impact of consumer’s preferences, economies of scale, manufacturing rights and patents, existing distribution channels, switching costs, government regulations and brand loyalty. 
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2019
Forecast Period Covered 2019 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Product Type Cimzia (Certolizumab Pegol), Enbrel (Etanercept), Humira ( Adalimumab), Otezla (Apremilast), Remicade (Infliximab), Simponi (Golimumab)
Applications Clinic, Hospital, Others
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered Apogenix, AryoGen Biopharma, Bionovis, CASI Pharmaceuticals, Celltrion, Celgene Corporation, Delenex Therapeutics, Dexa Medica, EPIRUS Biopharmaceuticals, Janssen Biotech, GlaxoSmithKline, HanAll Biopharma, Intas Pharmaceuticals, LEO Pharma, LG Life Sciences, MedImmune, Momenta Pharmaceuticals, Novartis, PROBIOMED, Reliance Life Sciences, Sandoz, Samsung Bioepis, Sanofi-Aventis, Shanghai CP Guojian Pharmaceutical, Shanghai Pharmaceuticals, Simcere Pharmaceutical, Toyama Chemical, Tsumura, UCB, Zydus Cadila

Tumor Necrosis Factor Inhibitors Drug Market Segment Analysis:
The Tumor Necrosis Factor Inhibitors Drug market research report segments the market based on its types, applications and end-use industry. All the segments of the market are analyzed and evaluated based on current and future trends of the market. The data for the segments and its categories is provided from 2018 to 2028. 

Tumor Necrosis Factor Inhibitors Drug Market, by Type: Cimzia (Certolizumab Pegol), Enbrel (Etanercept), Humira ( Adalimumab), Otezla (Apremilast), Remicade (Infliximab), Simponi (Golimumab)

Tumor Necrosis Factor Inhibitors Drug Market, by Application: Clinic, Hospital, Others

Major Key Players for Global Tumor Necrosis Factor Inhibitors Drug Market:
The Tumor Necrosis Factor Inhibitors Drug market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Apogenix, AryoGen Biopharma, Bionovis, CASI Pharmaceuticals, Celltrion, Celgene Corporation, Delenex Therapeutics, Dexa Medica, EPIRUS Biopharmaceuticals, Janssen Biotech, GlaxoSmithKline, HanAll Biopharma, Intas Pharmaceuticals, LEO Pharma, LG Life Sciences, MedImmune, Momenta Pharmaceuticals, Novartis, PROBIOMED, Reliance Life Sciences, Sandoz, Samsung Bioepis, Sanofi-Aventis, Shanghai CP Guojian Pharmaceutical, Shanghai Pharmaceuticals, Simcere Pharmaceutical, Toyama Chemical, Tsumura, UCB, Zydus Cadila

Geographic Coverage for Tumor Necrosis Factor Inhibitors Drug Market:
The market research report on global Tumor Necrosis Factor Inhibitors Drug market offers complete analysis across various regions across the world. The Tumor Necrosis Factor Inhibitors Drug market is distributed into various regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The global leading market share as per the region is evaluated after considering Tumor Necrosis Factor Inhibitors Drug market revenue, sales, shares, recent developments, innovations and growth rates. This section of regional analysis provides widespread evaluation of the industry from various countries and regions.

North America Tumor Necrosis Factor Inhibitors Drug Market Value and Forecast
  • US
  • Canada

Europe Tumor Necrosis Factor Inhibitors Drug Market Value and Forecast
  • UK
  • Germany
  • France
  •  Rest of Europe

Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Value and Forecast
  • China
  • Japan
  • India
  • Rest of Asia Pacific

Latin America Tumor Necrosis Factor Inhibitors Drug Market Value and Forecast
  • Mexico
  • Brazil
  • Rest of Latin America

Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa



Key highlights of the Tumor Necrosis Factor Inhibitors Drug market report:
  • The report provides key trends of the global Tumor Necrosis Factor Inhibitors Drug market
  • The report also covers consumer preferences and current industry growth
  • Key products or solutions offered by the main players in the Tumor Necrosis Factor Inhibitors Drug industry
  • The report covers all the recent developments of the Tumor Necrosis Factor Inhibitors Drug market and helps to provide current industry updates
  • The report covers a detailed look over the global Tumor Necrosis Factor Inhibitors Drug Industry and provides with significant actionable insights
  • The Tumor Necrosis Factor Inhibitors Drug market estimation from 2020-2028 and historical data for 2018 and 2019
  • The market study also provides data on changing market dynamics, market intelligence, current and future market trends
  • The report also analyses the microeconomic and macroeconomic factors that are affecting the global Tumor Necrosis Factor Inhibitors Drug market
  • In-depth analysis of the market’s competitive landscape and detailed information about the vendors
  • The report also offers key market drivers, restrains, trends and opportunities with present and future impact on the market
  • Detailed information about the major players or manufacturers of the global Tumor Necrosis Factor Inhibitors Drug market
  • Comprehensive analysis of the Tumor Necrosis Factor Inhibitors Drug market segments based on its types, applications and end-use industry

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Tumor Necrosis Factor Inhibitors Drug market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Tumor Necrosis Factor Inhibitors Drug market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

      2.  Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Tumor Necrosis Factor Inhibitors Drug market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Tumor Necrosis Factor Inhibitors Drug market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

      3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Tumor Necrosis Factor Inhibitors Drug market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Apogenix
  • AryoGen Biopharma
  • Bionovis
  • CASI Pharmaceuticals
  • Celltrion
  • Celgene Corporation
  • Delenex Therapeutics
  • Dexa Medica
  • EPIRUS Biopharmaceuticals
  • Janssen Biotech
  • GlaxoSmithKline
  • HanAll Biopharma
  • Intas Pharmaceuticals
  • LEO Pharma
  • LG Life Sciences
  • MedImmune
  • Momenta Pharmaceuticals
  • Novartis
  • PROBIOMED
  • Reliance Life Sciences
  • Sandoz
  • Samsung Bioepis
  • Sanofi-Aventis
  • Shanghai CP Guojian Pharmaceutical
  • Shanghai Pharmaceuticals
  • Simcere Pharmaceutical
  • Toyama Chemical
  • Tsumura
  • UCB
  • Zydus Cadila
  • Cimzia (Certolizumab Pegol)
  • Enbrel (Etanercept)
  • Humira ( Adalimumab)
  • Otezla (Apremilast)
  • Remicade (Infliximab)
  • Simponi (Golimumab)
  • Clinic
  • Hospital
  • Others

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summary
     2.1. Global Tumor Necrosis Factor Inhibitors Drug Market Snapshot
          2.1.1. Global Tumor Necrosis Factor Inhibitors Drug Market By Type,2019
               2.1.1.1.Cimzia (Certolizumab Pegol)
               2.1.1.2.Enbrel (Etanercept)
               2.1.1.3.Humira ( Adalimumab)
               2.1.1.4.Otezla (Apremilast)
               2.1.1.5.Remicade (Infliximab)
               2.1.1.6.Simponi (Golimumab)
          2.1.2. Global Tumor Necrosis Factor Inhibitors Drug Market By Application,2019
               2.1.2.1.Clinic
               2.1.2.2.Hospital
               2.1.2.3.Others
          2.1.3. Global Tumor Necrosis Factor Inhibitors Drug Market By End-use,2019
          2.1.4. Global Tumor Necrosis Factor Inhibitors Drug Market By Geography,2019

3. Global Tumor Necrosis Factor Inhibitors Drug Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Type, 2018 – 2028

5. Global Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Application, 2018 – 2028

6. Global Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By End-use, 2018 – 2028

7. Global Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Tumor Necrosis Factor Inhibitors Drug Market Analysis, 2018 – 2028 
          7.2.1. North America Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Tumor Necrosis Factor Inhibitors Drug Market Analysis, 2018 – 2028 
          7.3.1.  Europe Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Tumor Necrosis Factor Inhibitors Drug Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Tumor Necrosis Factor Inhibitors Drug Market Analysis, 2018 – 2028 
          7.6.1.  MEA Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Tumor Necrosis Factor Inhibitors Drug Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Tumor Necrosis Factor Inhibitors Drug Providers
        8.4.1 Apogenix
                8.1.1 Business Description
                8.1.2 Apogenix Geographic Operations
                8.1.3 Apogenix Financial Information
                8.1.4 Apogenix Product Positions/Portfolio
                8.1.5 Apogenix Key Developments
        8.4.2 AryoGen Biopharma
                8.2.1 Business Description
                8.2.2 AryoGen Biopharma Geographic Operations
                8.2.3 AryoGen Biopharma Financial Information
                8.2.4 AryoGen Biopharma Product Positions/Portfolio
                8.2.5 AryoGen Biopharma Key Developments
        8.4.3 Bionovis
                8.3.1 Business Description
                8.3.2 Bionovis Geographic Operations
                8.3.3 Bionovis Financial Information
                8.3.4 Bionovis Product Positions/Portfolio
                8.3.5 Bionovis Key Developments
        8.4.4 CASI Pharmaceuticals
                8.4.1 Business Description
                8.4.2 CASI Pharmaceuticals Geographic Operations
                8.4.3 CASI Pharmaceuticals Financial Information
                8.4.4 CASI Pharmaceuticals Product Positions/Portfolio
                8.4.5 CASI Pharmaceuticals Key Developments
        8.4.5 Celltrion
                8.5.1 Business Description
                8.5.2 Celltrion Geographic Operations
                8.5.3 Celltrion Financial Information
                8.5.4 Celltrion Product Positions/Portfolio
                8.5.5 Celltrion Key Developments
        8.4.6 Celgene Corporation
                8.6.1 Business Description
                8.6.2 Celgene Corporation Geographic Operations
                8.6.3 Celgene Corporation Financial Information
                8.6.4 Celgene Corporation Product Positions/Portfolio
                8.6.5 Celgene Corporation Key Developments
        8.4.7 Delenex Therapeutics
                8.7.1 Business Description
                8.7.2 Delenex Therapeutics Geographic Operations
                8.7.3 Delenex Therapeutics Financial Information
                8.7.4 Delenex Therapeutics Product Positions/Portfolio
                8.7.5 Delenex Therapeutics Key Developments
        8.4.8 Dexa Medica
                8.8.1 Business Description
                8.8.2 Dexa Medica Geographic Operations
                8.8.3 Dexa Medica Financial Information
                8.8.4 Dexa Medica Product Positions/Portfolio
                8.8.5 Dexa Medica Key Developments
        8.4.9 EPIRUS Biopharmaceuticals
                8.9.1 Business Description
                8.9.2 EPIRUS Biopharmaceuticals Geographic Operations
                8.9.3 EPIRUS Biopharmaceuticals Financial Information
                8.9.4 EPIRUS Biopharmaceuticals Product Positions/Portfolio
                8.9.5 EPIRUS Biopharmaceuticals Key Developments
        8.4.10 Janssen Biotech
                8.10.1 Business Description
                8.10.2 Janssen Biotech Geographic Operations
                8.10.3 Janssen Biotech Financial Information
                8.10.4 Janssen Biotech Product Positions/Portfolio
                8.10.5 Janssen Biotech Key Developments
        8.4.11 GlaxoSmithKline
                8.11.1 Business Description
                8.11.2 GlaxoSmithKline Geographic Operations
                8.11.3 GlaxoSmithKline Financial Information
                8.11.4 GlaxoSmithKline Product Positions/Portfolio
                8.11.5 GlaxoSmithKline Key Developments
        8.4.12 HanAll Biopharma
                8.12.1 Business Description
                8.12.2 HanAll Biopharma Geographic Operations
                8.12.3 HanAll Biopharma Financial Information
                8.12.4 HanAll Biopharma Product Positions/Portfolio
                8.12.5 HanAll Biopharma Key Developments
        8.4.13 Intas Pharmaceuticals
                8.13.1 Business Description
                8.13.2 Intas Pharmaceuticals Geographic Operations
                8.13.3 Intas Pharmaceuticals Financial Information
                8.13.4 Intas Pharmaceuticals Product Positions/Portfolio
                8.13.5 Intas Pharmaceuticals Key Developments
        8.4.14 LEO Pharma
                8.14.1 Business Description
                8.14.2 LEO Pharma Geographic Operations
                8.14.3 LEO Pharma Financial Information
                8.14.4 LEO Pharma Product Positions/Portfolio
                8.14.5 LEO Pharma Key Developments
        8.4.15 LG Life Sciences
                8.15.1 Business Description
                8.15.2 LG Life Sciences Geographic Operations
                8.15.3 LG Life Sciences Financial Information
                8.15.4 LG Life Sciences Product Positions/Portfolio
                8.15.5 LG Life Sciences Key Developments
        8.4.16 MedImmune
                8.16.1 Business Description
                8.16.2 MedImmune Geographic Operations
                8.16.3 MedImmune Financial Information
                8.16.4 MedImmune Product Positions/Portfolio
                8.16.5 MedImmune Key Developments
        8.4.17 Momenta Pharmaceuticals
                8.17.1 Business Description
                8.17.2 Momenta Pharmaceuticals Geographic Operations
                8.17.3 Momenta Pharmaceuticals Financial Information
                8.17.4 Momenta Pharmaceuticals Product Positions/Portfolio
                8.17.5 Momenta Pharmaceuticals Key Developments
        8.4.18 Novartis
                8.18.1 Business Description
                8.18.2 Novartis Geographic Operations
                8.18.3 Novartis Financial Information
                8.18.4 Novartis Product Positions/Portfolio
                8.18.5 Novartis Key Developments
        8.4.19 PROBIOMED
                8.19.1 Business Description
                8.19.2 PROBIOMED Geographic Operations
                8.19.3 PROBIOMED Financial Information
                8.19.4 PROBIOMED Product Positions/Portfolio
                8.19.5 PROBIOMED Key Developments
        8.4.20 Reliance Life Sciences
                8.20.1 Business Description
                8.20.2 Reliance Life Sciences Geographic Operations
                8.20.3 Reliance Life Sciences Financial Information
                8.20.4 Reliance Life Sciences Product Positions/Portfolio
                8.20.5 Reliance Life Sciences Key Developments
        8.4.21 Sandoz
                8.21.1 Business Description
                8.21.2 Sandoz Geographic Operations
                8.21.3 Sandoz Financial Information
                8.21.4 Sandoz Product Positions/Portfolio
                8.21.5 Sandoz Key Developments
        8.4.22 Samsung Bioepis
                8.22.1 Business Description
                8.22.2 Samsung Bioepis Geographic Operations
                8.22.3 Samsung Bioepis Financial Information
                8.22.4 Samsung Bioepis Product Positions/Portfolio
                8.22.5 Samsung Bioepis Key Developments
        8.4.23 Sanofi-Aventis
                8.23.1 Business Description
                8.23.2 Sanofi-Aventis Geographic Operations
                8.23.3 Sanofi-Aventis Financial Information
                8.23.4 Sanofi-Aventis Product Positions/Portfolio
                8.23.5 Sanofi-Aventis Key Developments
        8.4.24 Shanghai CP Guojian Pharmaceutical
                8.24.1 Business Description
                8.24.2 Shanghai CP Guojian Pharmaceutical Geographic Operations
                8.24.3 Shanghai CP Guojian Pharmaceutical Financial Information
                8.24.4 Shanghai CP Guojian Pharmaceutical Product Positions/Portfolio
                8.24.5 Shanghai CP Guojian Pharmaceutical Key Developments
        8.4.25 Shanghai Pharmaceuticals
                8.25.1 Business Description
                8.25.2 Shanghai Pharmaceuticals Geographic Operations
                8.25.3 Shanghai Pharmaceuticals Financial Information
                8.25.4 Shanghai Pharmaceuticals Product Positions/Portfolio
                8.25.5 Shanghai Pharmaceuticals Key Developments
        8.4.26 Simcere Pharmaceutical
                8.26.1 Business Description
                8.26.2 Simcere Pharmaceutical Geographic Operations
                8.26.3 Simcere Pharmaceutical Financial Information
                8.26.4 Simcere Pharmaceutical Product Positions/Portfolio
                8.26.5 Simcere Pharmaceutical Key Developments
        8.4.27 Toyama Chemical
                8.27.1 Business Description
                8.27.2 Toyama Chemical Geographic Operations
                8.27.3 Toyama Chemical Financial Information
                8.27.4 Toyama Chemical Product Positions/Portfolio
                8.27.5 Toyama Chemical Key Developments
        8.4.28 Tsumura
                8.28.1 Business Description
                8.28.2 Tsumura Geographic Operations
                8.28.3 Tsumura Financial Information
                8.28.4 Tsumura Product Positions/Portfolio
                8.28.5 Tsumura Key Developments
        8.4.29 UCB
                8.29.1 Business Description
                8.29.2 UCB Geographic Operations
                8.29.3 UCB Financial Information
                8.29.4 UCB Product Positions/Portfolio
                8.29.5 UCB Key Developments
        8.4.30 Zydus Cadila
                8.30.1 Business Description
                8.30.2 Zydus Cadila Geographic Operations
                8.30.3 Zydus Cadila Financial Information
                8.30.4 Zydus Cadila Product Positions/Portfolio
                8.30.5 Zydus Cadila Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Tumor Necrosis Factor Inhibitors Drug Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Tumor Necrosis Factor Inhibitors Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Tumor Necrosis Factor Inhibitors Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Tumor Necrosis Factor Inhibitors Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Tumor Necrosis Factor Inhibitors Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Tumor Necrosis Factor Inhibitors Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Tumor Necrosis Factor Inhibitors Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Tumor Necrosis Factor Inhibitors Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Tumor Necrosis Factor Inhibitors Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Tumor Necrosis Factor Inhibitors Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Tumor Necrosis Factor Inhibitors Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Tumor Necrosis Factor Inhibitors Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Tumor Necrosis Factor Inhibitors Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Tumor Necrosis Factor Inhibitors Drug: Market Segmentation 
FIG. 2 Global Tumor Necrosis Factor Inhibitors Drug Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Tumor Necrosis Factor Inhibitors Drug Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Tumor Necrosis Factor Inhibitors Drug Market, By Application, 2019 (US$ Mn) 
FIG. 6 Global Tumor Necrosis Factor Inhibitors Drug Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Tumor Necrosis Factor Inhibitors Drug Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Tumor Necrosis Factor Inhibitors Drug Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Tumor Necrosis Factor Inhibitors Drug Providers, 2019
FIG. 11 Global Tumor Necrosis Factor Inhibitors Drug Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Tumor Necrosis Factor Inhibitors Drug Market Revenue Contribution, By Application, 2019 & 2028 (Value %) 
FIG. 13 Global Tumor Necrosis Factor Inhibitors Drug Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Tumor Necrosis Factor Inhibitors Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Tumor Necrosis Factor Inhibitors Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Tumor Necrosis Factor Inhibitors Drug Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Tumor Necrosis Factor Inhibitors Drug Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Tumor Necrosis Factor Inhibitors Drug market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Tumor Necrosis Factor Inhibitors Drug Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Tumor Necrosis Factor Inhibitors Drug Market Value, By Segment1, 2018 – 2028
TABLE  North America Tumor Necrosis Factor Inhibitors Drug Market Value, By Segment2, 2018 – 2028
TABLE  North America Tumor Necrosis Factor Inhibitors Drug Market Value, By Country, 2018 – 2028
TABLE  Europe Tumor Necrosis Factor Inhibitors Drug Market Value, By Segment1, 2018 – 2028
TABLE  Europe Tumor Necrosis Factor Inhibitors Drug Market Value, By Segment2, 2018 – 2028
TABLE  Europe Tumor Necrosis Factor Inhibitors Drug Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Value, By Country, 2018 – 2028
TABLE  Latin America Tumor Necrosis Factor Inhibitors Drug Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Tumor Necrosis Factor Inhibitors Drug Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Tumor Necrosis Factor Inhibitors Drug Market Value, By Country, 2018 – 2028
TABLE  MEA Tumor Necrosis Factor Inhibitors Drug Market Value, By Segment1, 2018 – 2028
TABLE  MEA Tumor Necrosis Factor Inhibitors Drug Market Value, By Segment2, 2018 – 2028
TABLE  MEA Tumor Necrosis Factor Inhibitors Drug Market Value, By Country, 2018 – 2028
TABLE  Apogenix: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AryoGen Biopharma: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bionovis: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  CASI Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Celltrion: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Celgene Corporation: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Delenex Therapeutics: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Dexa Medica: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  EPIRUS Biopharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Janssen Biotech: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  HanAll Biopharma: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Intas Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  LEO Pharma: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  LG Life Sciences: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  MedImmune: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Momenta Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  PROBIOMED: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Reliance Life Sciences: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sandoz: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Samsung Bioepis: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sanofi-Aventis: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Shanghai CP Guojian Pharmaceutical: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Shanghai Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Simcere Pharmaceutical: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Toyama Chemical: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Tsumura: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  UCB: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Zydus Cadila: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Tumor Necrosis Factor Inhibitors Drug Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Tumor Necrosis Factor Inhibitors Drug Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Tumor Necrosis Factor Inhibitors Drug Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Tumor Necrosis Factor Inhibitors Drug Market, By Geography, 2019 (US$ Mn)
FIG.  Global Tumor Necrosis Factor Inhibitors Drug Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Tumor Necrosis Factor Inhibitors Drug Providers, 2016
FIG.  Global Tumor Necrosis Factor Inhibitors Drug Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Cimzia (Certolizumab Pegol) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Enbrel (Etanercept) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Humira ( Adalimumab) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Otezla (Apremilast) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Remicade (Infliximab) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Simponi (Golimumab) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Tumor Necrosis Factor Inhibitors Drug Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Clinic Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Hospital Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Tumor Necrosis Factor Inhibitors Drug Market Value, 2018 – 2028, (US$ Mn)